Literature DB >> 33493688

Postoperative opioid administration characteristics associated with opioid-induced respiratory depression: Results from the PRODIGY trial.

Richard D Urman1, Ashish K Khanna2, Sergio D Bergese3, Wolfgang Buhre4, Maria Wittmann5, Morgan Le Guen6, Frank J Overdyk7, Fabio Di Piazza8, Leif Saager9.   

Abstract

STUDY
OBJECTIVE: Opioid administration for pain in general care floor patients remains common, and can lead to adverse outcomes, including respiratory compromise. The PRODIGY trial found that among ward patients receiving parenteral opioids, 46% experienced ≥1 respiratory depression episode. The objective of this analysis was to evaluate the geographic differences of opioid administration and examine the association between opioid administration characteristics and the occurrence of respiratory depression.
DESIGN: Prospective observational trial.
SETTING: 16 general care medical and surgical wards in Asia, Europe, and the United States. PATIENTS: 1335 patients receiving parenteral opioids.
INTERVENTIONS: Blinded, alarm-silenced continuous capnography and pulse oximetry monitoring. MEASUREMENTS: Opioid-induced respiratory depression, defined as respiratory rate ≤ 5 bpm, SpO2 ≤ 85%, or ETCO2 ≤ 15 or ≥ 60 mmHg for ≥3 min; apnea episode lasting >30 s; or any respiratory opioid-related adverse event.
RESULTS: Across all patients, 58% received only long-acting opioids, 16% received only short-acting (<3 h) opioids, and 21% received a combination of short- and long-acting (≥3 h) opioids. The type and median total morphine milligram equivalent (MME) of opioid administered varied significantly by region, with 31.5 (12.5-76.7) MME, 31.0 (6.2-99.0) MME, and 7.2 (1.7-18.7) MME in the United States, Europe, and Asia, respectively (p < 0.001). Considering only postoperative opioids, 54% (N = 119/220) and 45% (N = 347/779) of patients receiving only short-acting opioids or only long-acting opioids experienced ≥1 episode of opioid-induced respiratory depression, respectively. Multivariable analysis identified post-procedure tramadol (OR 0.62, 95% CI 0.424-0.905, p = 0.0133) and post-procedure epidural opioids (OR 0.485, 95% CI 0.322-0.731, p = 0.0005) being associated with a significant reduction in opioid-induced respiratory depression.
CONCLUSIONS: Despite varying opioid administration characteristics between Asia, Europe, and the United States, opioid-induced respiratory depression remains a common global problem on general care medical and surgical wards. While the use of post-procedure tramadol or post-procedure epidural opioids may reduce the incidence of respiratory depression, continuous monitoring is also necessary to ensure patient safety when receiving postoperative opioids. REGISTRATION NUMBER: www.clinicaltrials.gov, ID: NCT02811302.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Continuous monitoring; General care floor; Opioid; Respiratory compromise; Respiratory depression

Mesh:

Substances:

Year:  2021        PMID: 33493688     DOI: 10.1016/j.jclinane.2021.110167

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  2 in total

1.  The Impact of Perioperative Multimodal Pain Management on Postoperative Outcomes in Patients (Aged 75 and Older) Undergoing Short-Segment Lumbar Fusion Surgery.

Authors:  Shuaikang Wang; Tongtong Zhang; Peng Wang; Xiangyu Li; Chao Kong; Wenzhi Sun; Shibao Lu
Journal:  Pain Res Manag       Date:  2022-02-27       Impact factor: 3.037

2.  Nocturnal Oxygen Desaturation Index Correlates with Respiratory Depression in Post-Surgical Patients Receiving Opioids - A Post-Hoc Analysis from the Prediction of Opioid-Induced Respiratory Depression in Patients Monitored by Capnography (PRODIGY) Study.

Authors:  Lydia Q N Liew; Lawrence S C Law; Edwin Seet; Fabio Di Piazza; Katherine E Liu; Ming Ann Sim; Vanessa T Y Chua; Toby N Weingarten; Ashish K Khanna; Lian Kah Ti
Journal:  Nat Sci Sleep       Date:  2022-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.